Screener
Amylyx Pharmaceuticals, Inc. AMLX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:04 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336682
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Milestone payments related to IPR&D | (4,000) | — |
| Purchases of investments | (200,505) | (142,637) |
| Proceeds from maturities of marketable securities | 91,000 | 122,000 |
| Net cash used in investing activities | (113,535) | (20,665) |
| Cash flows provided by financing activities: | ||
| Proceeds from financings, net of issuance costs | — | 65,577 |
| Proceeds from exercise of stock options and RSUs vesting | 9,132 | 1,042 |
| Withholding taxes paid on stock-based awards | (4,436) | (988) |
Item 1. Financial Statements.
FAQ
- What is Amylyx Pharmaceuticals, Inc.'s investing cash flow?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported investing cash flow of -$149.8M in Q2 2026.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Amylyx Pharmaceuticals, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude